Evidence map›Paper›PMID 32454672›Full record

ArticleTurkish journal of pharmaceutical sciences2018

Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide.

Hanif Shirinzadeh, Sibel Süzen, Nurten Altanlar, Andrew D Westwell

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Antifungal Activities of Multi-Halogenated Indoles Against Drug-ResistantInternational journal of molecular sciences · 2025
    Article
  6. Review
  7. The In Vitro Potential of 1-(1Microorganisms · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hanif ShirinzadehErzincan University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Erzincan, Turkey.ORCID https://orcid.org/0000-0001-9663-9199
Sibel SüzenAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey.ORCID https://orcid.org/0000-0003-3413-6152
Nurten AltanlarAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Ankara, Turkey.ORCID https://orcid.org/0000-0003-2977-2269
Andrew D WestwellCardiff University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Cardiff, United Kingdom.ORCID https://orcid.org/0000-0002-5166-9236

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn new antimicrobial drug development studies, indole and its derivatives create an important class of compounds. In addition, azoles and their derivatives were recognized to be associated with a variety of biologic activities such as antibacterial and antifungal. In this study antimicrobial activities of some indole derivatives mainly substituted with 1,2,4-triazole, 1,3,4-thiadiazole and hydrazinecarbothioamide were investigated to evaluate their efficacy. MATERIALS AND

methodsThe efficacy of new compounds was evaluated using 2-fold serial dilutions against

resultsThe MIC was determined for test compounds and for the reference standards sultamicillin, ampicillin, fluconazole, and ciprofloxacin.

conclusionThe compounds possessed a broad spectrum of activity having MIC values of 3.125-50 µg/mL against the tested microorganisms. This study provides valuable evidence that the indole-triazole derivative compound 3d holds significant promise as a novel antibacterial and antifungal lead compound.

Indexed as

1234-thiadiazole4-triazoleC. kruseiIndoleMRSA

Identifiers

PMID32454672
PMCPMC7227843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.